Christopher Peetz

CEO Peetz sells 30,000 shares ($2.9M) via scheduled 10b5-1 plan; retains 194,309 shares plus 128,487 stock options

Christopher Peetz executed 6 separate sales totaling 30,000 shares for $2,875,103.34 at prices ranging from $94.64 to $99.66, reducing his non-derivative holdings from 224,309 to 194,309 shares (-13.4%). This transaction is part of a pre-arranged 10b5-1 trading plan adopted on 2026-03-02, making it scheduled rather than discretionary. The sales occurred as the stock trades at $92.17, down 19.8% from its 52-week high of $114.99, though it is up 30 days (-4.5%) and up 90 days (-0.9%). At MIRM specifically, Peetz's prior 5 sales show mixed near-term outcomes: his most recent sale on 2026-03-16 was followed by 30-day and 90-day gains of 4.8% and 4.7% respectively, while his 2026-02-02 sale saw subsequent declines of 9.9% and 6.6%. The company remains unprofitable (net income of $-790,155,000.00 in the most recent period) despite annual revenue growth of +54.7%, reflecting an early-stage or turnaround profile.

CEO Peetz sold 40,985 shares of MIRM at $91.98 on 2026-03-16 for $3.8M; now holds 194,309 shares post-sale.

Christopher Peetz, CEO of Mirum Pharmaceuticals, divested 40,985 shares valued at $3,769,714.23, reducing his stake by -17.4% versus pre-transaction holdings of 235,294 shares. The sale occurred at $91.98, now trading 11.1% below the 52-week high of $108.62. Peetz's cross-ticker timing record shows a 40.00% well-timed rate with 8 prior sells averaging +7.7% returns over 90 days—indicating his recent open-market sales have often preceded modest gains rather than declines. At MIRM specifically, his prior 5 trades show 0 of 2 measurable 90-day outcomes were well-timed, with recent sells (2025-08-11 and 2025-08-07) returning +9.8% and +26.9% respectively—both positive, meaning the stock rallied after those sales. The company trades at a P/E of 254.08 with company-wide annual losses despite +54.7% revenue growth, signaling a high-risk valuation profile. This sale follows two prior MIRM sales in February and January 2026 with mixed results, and occurs amid 90-day performance of +39.9%, suggesting the executive is reducing exposure after a substantial recent rally.

CEO Peetz sells 9,108 MIRM shares at $103.30; holds 160.3K shares post-transaction as stock approaches 52-week high.

Christopher Peetz, Chief Executive Officer, sold 9,108 shares at $103.30 on 2026-02-02, reducing his holdings by 5.4% to 160.3K shares. The sale occurred at a price $2.15 below the current $105.45, with the stock at its 52-week high of $105.45 and up 35.1% over 30 days and 50.4% over 90 days. At Mirum Pharmaceuticals specifically, Peetz's prior measurable sales (2025-08-11 and 2025-08-07) saw the stock rise 9.8% and 26.9% respectively in the 90 days following, yielding a 0% well-timed rate at this ticker. The company fundamentals show revenue of $133.0M with annual growth of 80.8%, though the business remained unprofitable on a full-year basis. The recent strength in the stock price—reaching its 52-week high just days after this transaction—stands against Peetz's same-ticker history of selling before subsequent gains rather than declines.

CEO Peetz sells 6,831 shares at $96.19 (near 52-week high); stock up 40.9% in 90 days

Christopher Peetz, Chief Executive Officer of Mirum Pharmaceuticals, sold 6,831 shares at $96.19 on 2026-01-26, reducing his holdings from 176.2K to 169.4K shares. The transaction occurred at a price 3.1% below the current $99.27 (52-week high), and the stock has appreciated 40.9% over the prior 90 days and 25.2% over the prior 30 days. His same-ticker history at MIRM shows mixed timing outcomes: 2 of 3 measurable prior sales (2025-08-11 and 2025-08-07) were followed by further gains, suggesting the stock continued higher after his prior exits. The company reported strong fundamentals with $133.0M quarterly revenue and 80.8% annual revenue growth, though full-year results remained unprofitable. This sale occurs during a steep uptrend and near multiyear highs, where post-sale price momentum has historically persisted at this ticker.

CEO Peetz sold 7,098 shares at $93.33; stock near 52-week high (+34.7% in 90 days). Prior MIRM sells 40% well-timed.

Christopher Peetz, CEO of Mirum Pharmaceuticals, sold 7,098 shares for $662,422.27 on 2026-01-22, reducing his holdings from 170,831 to 163,733 shares. The sale occurred when MIRM traded at $93.33, near its 52-week high of $96.03 and following a strong 90-day rally of +34.7%. Across his prior 5 sales at MIRM, 2 were well-timed at the 90-day mark (40% success rate), a mixed pattern compared to his cross-ticker track record of 40.00% 90-day well-timed rate. While fundamentals show 80.8% annual revenue growth to $133.0M, the company remains unprofitable on a full-year basis with net income of $2.9M in the latest quarter, leaving questions about sustainability at the current $4.8B market valuation.

CEO Peetz Christopher sold 40,000 shares of MIRM at $62.00 on 2025-08-11; stock now at $64.72, down from 52-week high of $65.87.

Christopher Peetz, MIRM's CEO, sold 40,000 shares (40.0K shares) for $2,480,000.00 on 2025-08-11, reducing his holdings by 22.4% to 138,641 shares. The sale occurred near the company's 52-week highs ($65.87), with the stock currently trading at $64.72, -1.8% from that peak. Despite near-term weakness and a 30-day return of -6.8% on his cross-ticker sales historically, MIRM itself has rallied +22.9% over 30 days and +45.8% over 90 days post-announcement, placing this sale at a notably inopportune exit point relative to subsequent price action. The company remains unprofitable (net income $-5.9M) despite strong annual revenue growth of +80.8%, and Peetz's prior three measurable sales at MIRM show 2 of 3 were well-timed at the 90-day mark, making this sale's departure from that pattern noteworthy for investors monitoring management conviction.

CEO Peetz Christopher sells 40,000 MIRM shares at $55.25, reducing stake by 22.4% to 138,641 shares amid recent 35.5% stock rally.

CEO Christopher Peetz executed a substantial sale of 40,000 shares at $55.25 on 2025-08-07, reducing his holdings by 22.4% from 178,641 to 138,641 shares and realizing $2,210,040.00 in proceeds. The sale occurs at a notably unfavorable timing relative to the stock's near-term performance: the transaction price of $55.25 sits 7.8% below the current price of $59.97, and the stock has gained 35.5% over the past 90 days, including a 12.2% surge in the past 30 days. This sale follows a pattern of underperformance in his prior same-ticker sales at MIRM: the 2025-03-17 sale returned +12.2% over 90 days, while the 2025-03-03 sales posted -3.4% and -4.6% 90-day returns. The company's fundamentals show strong revenue growth of 80.8% annually, yet it remains unprofitable (net income of $-5,861,000.00 on the latest quarter's $127,785,000.00 revenue), adding complexity to the valuation signal. For investors, the material question is whether the CEO's liquidation of over one-fifth of his stake reflects informed concern about sustainable growth at a valuation now 7.8% above his sale price, or simply reflects portfolio actions independent of forward outlook.

CEO Peetz sells 27.3K MIRM shares at $44.21 (−16.6% from 52-week high); reduces stake to 138.6K; two prior sales in March

Christopher Peetz, Chief Executive Officer of Mirum Pharmaceuticals, sold 27,279 shares on 2025-03-17 at $44.21, generating $1,206,121.89 in proceeds and reducing his holdings by 16.4% to 138.6K shares. This is his second discrete sale in the same month—a prior sale occurred on 2025-03-03—signaling a sustained reduction of his equity stake within a narrow timeframe. The company is unprofitable with net income of $-14.2M over its most recent full fiscal year, though quarterly revenue of $90.4M represents strong 80.8% annual growth. At the transaction price of $44.21, the stock was already 16.6% below its 52-week high of $53.16 and has declined a further 11.4% over the subsequent 30 days, trading now at $44.31. The cumulative pattern of consecutive month-end sales by the CEO during a period of recent price weakness and persistent net losses may warrant closer examination of management's confidence in near-term fundamentals and burn rate trajectory.

CEO Peetz sold 40,000 shares (40.0K) for $1.9M across 2 transactions at MIRM, reducing holdings by 25.7%

Christopher Peetz, Chief Executive Officer of Mirum Pharmaceuticals, executed 2 separate sales on 2025-03-03 totaling 40,000 shares for $1,876,352.64 at a blended average price of $46.91, reducing his holdings from 155,920 shares to 115,920 shares. The current stock price of $45.22 is -14.9% from the 52-week high of $53.16, and the sales occurred above current market levels. Mirum reported Revenue $90,377,000.00 and Net income $-14,235,000.00 in its latest quarter, with the company unprofitable over its most recent full fiscal year, though Annual revenue growth reached +80.8%. A CEO reduction of 25.7% of holdings warrants investor attention to the underlying business trajectory and timing rationale, particularly given the company's current profitability challenges despite strong revenue growth.